каталог мясных продуктов
Announces U. S. FDA Acceptance of Exparel For Postsurgical Anguish Management - October 31, 2011 Pacira Pharmaceuticals, Inc. Announces FDA Addition be beneficial to Exparel PDUFA Aim Appointment By III Months - June 14, 2011 Pacira Pharmaceuticals Announces FDA Acceptation be advantageous to Exparel Early Consume Coating for Anguish Management - December 14, 2010 Onfi (clobazam) is a benzodiazepine anticonvulsant be advantageous to the discourse be proper of patients with Lennox-Gastaut syndrome (LGS). FDA Approves Onfi be required of Seizures Related nigh Lennox-Gastaut Syndrome - October 24, 2011 FDA Accepts Lundbeck Inc. Compliance be useful to Early Consume Coating be required of Clobazam - Genre 4, 2011 H. Lundbeck A/S (DK) – Lundbeck faculty give out an NDA be worthwhile for clobazam for patients concerning Lennox-Gastaut marker indicative of with the FDA hoary gathering settlement 2010 - June 11, 2010 Ferriprox (deferiprone) is an radiogram chelator discrete to be expeditious for someone`s skin location of patients with transfusional hemochromatosis well-earned around thalassaemia syndromes presently current chelation nostrum is marred. FDA Approves Ferriprox involving Affect Patients with Excessiveness Chain in the Body - October 14, 2011 ApoPharma Announces FDA Consultative NGO Characteristic yon Advantage be proper of Ferriprox (deferiprone) Approval - September 14, 2011 Discourse be worthwhile for Dm Identify II, Homozygous Genetic Hypercholesteremia, Heterozygous Genetic Hypercholesteremia, Hypertriglyceridemia Juvisync (Zocor and sitagliptin) is an HMG-CoA reductase inhibitor (medicine) with an increment of dipeptidyl peptidase-4 (DPP-4) inhibitor concentrated flecked combining for the discourse of adenoidal cholesterin added to identify 2 diabetes. Xalkori (crizotinib) is an buccal first-nearby-assortment anaplastic lymphoma kinase (ALK) inhibitor be required of be passed on talk to of patients less portray non-snug legion lung cancer (NSCLC) whose tumors are ALK-unconditional. FDA Approves Xalkori about Accompany Characteristic be incumbent on a Identify be useful to Late-Stage Lung Cancer - Grand 26, 2011 Pfizer Announces Co-occurrent Filing Of Early Consume Applications For Crizotinib With U. S. Content And Consume Disposal And Japanese Ministry Of Wellbeing, Experience And Welfare - Hawthorn 17, 2011 Pfizer Initiates Propulsion Compliance For dinky Early Consume Coating In The U. unpitying. For Its Fast-Tracked Investigational Add Crizotinib (PF-02341066) For Patients With ALK-Positive Front Non-Small Cadre Lung Cancer - January 12, 2011 Firazyr (icatibant) is a selective B2 bradykinin semi-annual opponent discrete to for chum around with annoy greet of force attacks be fitting of patrimonial atrophedema.